Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049195 | 0.84 | POLB (0.56) | POLBRXFP1L3MBTL1KDM4ELMNA | |
| SCHEMBL11507377 | 0.81 | POLB (0.56) | POLBRXFP1L3MBTL1KDM4ELMNA | |
| SCHEMBL11509901 | 0.80 | RXFP1 (0.55) | POLBRXFP1L3MBTL1KDM4ELMNA | |
| SCHEMBL4050347 | 0.79 | CA1 (0.39) | POLBSMN1; SMN2KMT2A | |
| SCHEMBL4030896 | 0.78 | RXFP1 (0.53) | POLBRXFP1L3MBTL1KDM4ELMNA | |
| SCHEMBL14052792 | 0.78 | POLB (0.62) | POLBRXFP1L3MBTL1KDM4ELMNA | |
| SCHEMBL19440209 | 0.77 | MAPT (0.56) | POLBKDM4ELMNASMN1; SMN2NCEH1 | |
| SCHEMBL3019686 | 0.76 | NCEH1 (0.58) | POLBRXFP1L3MBTL1KDM4ELMNA | |
| SCHEMBL3829305 | 0.76 | MAPT (0.55) | POLBRXFP1L3MBTL1KDM4ELMNA | |
| SCHEMBL30638066 | 0.76 | MAPT (0.55) | POLBRXFP1L3MBTL1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856083-A4 | CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF | UNIV MICHIGAN (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1856083-A2 | CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060247305-A1 | Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2006099193-A2 | CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-09-21 | — | — | WO | disclosed |
| US-7084149-B2 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| EP-1073640-B1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030236274-A1 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6573289-B1 | Naphthalene derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1073640-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054309-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236274-A1 | Naphthalene derivatives, their production and use | CYP17A1, CYP21A2, HSD17B1 | POLB 2225/4885RXFP1 3175/4885L3MBTL1 848/4885 |
| US-20060247305-A1 | Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof | BCL2, BAD, BAX | POLB 3663/4885RXFP1 4808/4885L3MBTL1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.